Paolo Tarantino: Our article on ADCs is among the top 10 most cited in CA Cancer Journal
Paolo Tarantino, shared a post on LinkedIn about a recent paper titled “Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies” published in the ACS Journals.
Authors: Paolo Tarantino, Roberto Carmagnani Pestana, Chiara Corti, Shanu Modi, Aditya Bardia, Sara M. Tolaney, Javier Cortes, Jean-Charles Soria, Giuseppe Curigliano.
“Proud to share that our article on the histology-agnostic expansion of ADCs in oncology is among the top 10 most cited articles in CA Cancer Journal, the highest impact factor journal in science! .
Thanks to Roberto Carmagnani Pestana, for co-leading this work, Chiara Corti for the great figures and all the expert coauthors that contributed to the article.”
Source: Paolo Tarantino/LinkedIn
Dr. Paolo Tarantino, MD, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan. His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023